GENERIC NAME: dapagliflozin
BRAND NAME: Farxiga
DRUG CLASS AND MECHANISM: Dapagliflozin (Farxiga) is an oral medication used to improve glycemia (blood glucose) control in patients with type 2 diabetes. Dapagliflozin is a sodium-glucose cotransporter (SGLT2) inhibitor. It is similar to canagliflozin (Invokana) and empagliflozin (Jardiance). SGLT2 is found in the kidney tubules and is responsible for reabsorbing the majority of glucose filtered out of the blood by the kidneys. By inhibiting SGLT2 dapagliflozin reduces the reabsorption of filtered glucose and consequently increases excretion of glucose in the urine. Dapagliflozin is not recommended for use in patients with moderate to severe kidney disease. Dapagliflozin was approved by the US FDA in January 2014.
PRESCRIBED FOR: Dapagliflozin is used to improve glycemia (blood glucose) control in adults with type 2 diabetes. For best results, dapagliflozin must be used along with dietary modifications and exercise. The safety and effectiveness of dapagliflozin has not been evaluated in patients younger than 18 years of age.
SIDE EFFECTS: The most common side effects associated with dapagliflozin were:
- vaginal yeast infections,
- yeast infections of the penis,
- nasopharyngitis (upper respiratory tract infections usually with associated sore throat, runny nose, nasal congestion, and sneezing),
- urinary tract infections (UTIs), and
- changes in urination (urinary urgency, urinating more often and in larger amounts).
Quick GuideDiabetes Diet: Healthy Meal Plans for Diabetes-Friendly Eating
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.